-- The most commonly observed adverse reactions in patients taking PRISTIQ
for MDD in short-term fixed-dose premarketing studies (incidence
greater than or equal to 5% and twice the rate of placebo in the 50- or
100-mg dose groups) were nausea, dizziness, insomnia, hyperhidrosis,
constipation, somnolence, decreased appetite, anxiety, and specific
male sexual function disorders.
Full prescribing information for PRISTIQ will be available at Pristiq.com.
Important Treatment Considerations for EFFEXOR XR
-- EFFEXOR XR is contraindicated in patients taking monoamine oxidase
-- Adult and pediatric patients taking antidepressants can experience
worsening of their depression and/or the emergence of suicidality. All
patients should be monitored appropriately and observed closely for
clinical worsening and suicidality, especially at the beginning of drug
therapy, or at the time of increases or decreases in dose. Anxiety,
agitation, panic attacks, insomnia, irritability, hostility,
aggressiveness, impulsivity, akathisia, hypomania, and mania have been
reported and may represent precursors to emerging suicidality. Stopping
or modifying therapy should be considered especially when symptoms are
severe, abrupt in onset, or not part of presenting symptoms.
-- The development of potentially life-threatening serotonin syndrome may
occur when EFFEXOR XR is coadministered with other drugs that may
affect the serotonergic neurotransmitter systems. Concomitant use of
EFFEXOR XR with MAOIs is contraindicated. If concomitant use of EFFEXOR
XR with an SSRI, SNRI, or a triptan is clinically warranted, careful
observation of the patient is advised. Concomitant use of EFFEXOR XR
with tryptophan supplements is not recom
|SOURCE Wyeth Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved